Von Hippel-lindau Syndrome: Disease Bioinformatics
Von Hippel-Lindau syndrome is an autosomal dominant genetic condition that causes tumors, called hemangioblastomas, in the brain, spinal cord, and eye. The syndrome is caused by a mutation in the VHL gene, which usually acts as a tumor suppressor. When the VHL gene is mutated, rapid growth is no longer regulated and tumors therefore begin to grow. Von Hippel-Lindau syndrome also increases the risk of developing a specific type of kidney cancer known as clear cell renal cell carcinoma. Symptoms of Von Hippel-Lindau syndrome include multiple hemangioblastomas or cysts in the brain, spinal cord, eye, or kidney. Genetic testing is used to diagnose individuals with the disease. Surgery and targeted cancer treatment is used to treat kidney cancer. The hemangioblastomas are often benign and therefore only need to be removed if the tumor interferes with the function of the organ. There is no cure for Von Hippel-Lindau syndrome yet, but focus on cancer research can help to uncover a cure.
Top Research Reagents
We have 4113 products for the study of Von Hippel-lindau Syndrome that can be applied to Chromatin Immunoprecipitation, Chromatin Immunoprecipitation (ChIP), Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot from our catalog of antibodies and ELISA kits.
Von Hippel-lindau Syndrome is also known as Cerebroretinal Angiomatosis, Hippel Lindau Disease, Hippel Lindau Syndrome, Hippel-lindau Disease, Lindau Disease.